| 2.455 0.105 (4.47%) | 04-14 09:54 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 3.05 |
1-year : | 3.34 |
| Resists | First : | 2.61 |
Second : | 2.85 |
| Pivot price | 2.43 |
|||
| Supports | First : | 2.23 |
Second : | 1.85 |
| MAs | MA(5) : | 2.41 |
MA(20) : | 2.48 |
| MA(100) : | 2.22  |
MA(250) : | 2.56 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 44.5 |
D(3) : | 36.9 |
| RSI | RSI(14): 46.6 |
|||
| 52-week | High : | 4.67 | Low : | 1.6 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ MBOT ] has closed above bottom band by 29.7%. Bollinger Bands are 28.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.4 - 2.41 | 2.41 - 2.42 |
| Low: | 2.2 - 2.22 | 2.22 - 2.22 |
| Close: | 2.33 - 2.35 | 2.35 - 2.37 |
Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company, through its ViRob, TipCAT, CardioSert, and Liberty micro-robotic technologies, developing Self Cleaning Shunt for the treatment of hydrocephalus and normal pressure hydrocephalus; a disposable robot for various endovascular interventional procedures; and a multi generation pipeline portfolio. It has 42 issued/allowed patents and 23 patent applications pending worldwide. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development. Microbot Medical Inc. was founded in 2010 and is based in Hingham, Massachusetts.
Tue, 14 Apr 2026
Microbot Medical (NASDAQ: MBOT) to spotlight LIBERTY robotic system FMR - Stock Titan
Tue, 14 Apr 2026
H.C. Wainwright reiterates Microbot Medical stock rating on full market release - Investing.com
Mon, 13 Apr 2026
Microbot Medical (MBOT) price target increased by 12.50% to 7.65 - MSN
Mon, 13 Apr 2026
Microbot Medical (MBOT) Expands LIBERTY Robot System Release in U.S. - GuruFocus
Mon, 13 Apr 2026
Microbot Medical begins U.S. full market release of LIBERTY after successful limited release - TradingView — Track All Markets
Mon, 13 Apr 2026
LIBERTY robot rollout widens for Microbot Medical (NASDAQ: MBOT) - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Instruments & Supplies
|
|
| Shares Out | 67 (M) |
| Shares Float | 67 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 17.5 (%) |
| Shares Short | 7,600 (K) |
| Shares Short P.Month | 7,360 (K) |
| EPS | -0.29 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.19 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -20.2 % |
| Return on Equity (ttm) | -31.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.21 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -11 (M) |
| Levered Free Cash Flow | -6 (M) |
| PE Ratio | -8.11 |
| PEG Ratio | 0 |
| Price to Book value | 1.97 |
| Price to Sales | 0 |
| Price to Cash Flow | -14.38 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|